Venous thromboembolism in women taking hormonal contraceptives

Hormonal contraceptives are a popular method of contraception, but their use has been associated with an increased risk for venous thromboembolism. In order to reduce such risk, these compounds have been changed in their dosage, chemical composition and route of administration. The absolute risk of death from pulmonary embolism in contraceptive users has been estimated to be 10.5 (95% CI: 6.2–16.6) per million woman-years. The safest option is an oral contraceptive containing levonorgestrel combined with a low dose of estrogen. Identifying women at increased risk for venous thromboembolism is difficult, and greater use of thromboprophylaxis during immobility or minor surgery should be warranted. Several authors have called for all women to be screened for thrombophilia before prescription of hormonal contraceptives, but its cost–effectiveness remains uncertain.

[1]  M. Monreal,et al.  Venous thromboembolism during pregnancy, postpartum or during contraceptive use , 2009, Thrombosis and Haemostasis.

[2]  E. Løkkegaard,et al.  Hormonal contraception and risk of venous thromboembolism: national follow-up study , 2009, BMJ : British Medical Journal.

[3]  F R Rosendaal,et al.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2009, BMJ : British Medical Journal.

[4]  M. Monreal,et al.  Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. , 2009, Thrombosis research.

[5]  I. Persson,et al.  Limited knowledge on progestogen‐only contraception and risk of venous thromboembolism , 2009, Acta obstetricia et gynecologica Scandinavica.

[6]  M. Monreal,et al.  Venous thromboembolism in women using hormonal contraceptives , 2009, Thrombosis and Haemostasis.

[7]  Kenneth J. Smith,et al.  Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? , 2008, Thrombosis and Haemostasis.

[8]  G. Guyatt,et al.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[9]  S. le Cessie,et al.  Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations , 2007, British journal of haematology.

[10]  I. Martinelli,et al.  Hormone therapy and thromboembolic disease , 2007, Current opinion in hematology.

[11]  H. Jick,et al.  Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. , 2007, Contraception.

[12]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[13]  J. van der Meer,et al.  Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. , 2007, Archives of internal medicine.

[14]  B. Kerlin,et al.  Recommendations for screening for thrombophilic tendencies in teenage females prior to contraceptive initiation. , 2006, Journal of pediatric and adolescent gynecology.

[15]  P. Langhorne,et al.  Screening for thrombophilia in high‐risk situations: a meta‐analysis and cost‐effectiveness analysis , 2005, British journal of haematology.

[16]  P. Langhorne,et al.  Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review , 2005, Thrombosis and Haemostasis.

[17]  S. Deitcher,et al.  Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.

[18]  E. Oger,et al.  Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.

[19]  F. Rosendaal,et al.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use , 2003, Thrombosis and Haemostasis.

[20]  M. O'Toole,et al.  Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period , 2003, British journal of sports medicine.

[21]  A. Algra,et al.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.

[22]  M. Prins,et al.  A Randomized Cross-over Study on the Effects of Levonorgestrel- and Desogestrel-containing Oral Contraceptives on the Anticoagulant Pathways , 2000, Thrombosis and Haemostasis.

[23]  C. Paul,et al.  Oral contraceptives and fatal pulmonary embolism , 2000, The Lancet.

[24]  J. Vandenbroucke,et al.  Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. , 2000, Archives of internal medicine.

[25]  R. Farmer,et al.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives , 1997, The Lancet.

[26]  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1996 .

[27]  World Health Organization Collaborative Study of Cardiov Contarception.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.

[28]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[29]  C. Colwell,et al.  Prevention of venous thromboembolism. , 1994, Chest.

[30]  P. Reitsma,et al.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation , 1994, The Lancet.

[31]  S. Eichinger,et al.  Consequences of thrombophilia screening for life quality in women before prescription of oral contraceptives and family members of VTE patients. , 2009, Hamostaseologie.

[32]  N. Veeger,et al.  Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. , 2007 .

[33]  K. Hedenmalm,et al.  Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives – an approach to specifying rates , 2005, European Journal of Epidemiology.

[34]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.